Cellular senescence mediates fibrotic pulmonary disease
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 18 of the 31 sources its claims cite were checked for support.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.
Overview
CoChat Summary
## TL;DR
This study links cellular senescence to idiopathic pulmonary fibrosis (IPF) by showing that senescence markers rise with disease severity in human lung tissue and that senescent fibroblast secretions are profibrotic. In a bleomycin mouse model, clearing senescent cells improved lung function and physical health, and dasatinib plus quercetin (DQ) reproduced the benefits of transgenic senescent-cell ablation.
## Key findings
- In human IPF lung samples, CDKN2A (p16) was significantly upregulated and increased with disease severity; higher pulmonary p16 expression correlated with reduced FVC, diffusion capacity, and SF-12 physical component score.
- In IPF tissue, p16-positive epithelial cells and fibroblasts were found in fibroblastic foci and honeycomb lung, and TAF-positive cells / γH2A.X foci were significantly increased relative to controls.
- In the bleomycin mouse model, lung injury increased whole-lung p16 expression by threefold, and SASP-related transcripts including Mcp1, Il6, Mmp12, Col1a1, and Tgfβ rose after bleomycin exposure.
- Senescent fibroblast conditioned medium was fibrogenic in vitro: it increased αSMA positivity to 62% vs 21% with control conditioned medium, increased traction forces, and induced fibrosis genes such as ACTA2, COL1A1, COL1A2, and FN1.
- In mice, senescent-cell clearance improved pulmonary/physical outcomes: Penh rose about twofold after bleomycin and was diminished by AP or DQ; lung compliance fell by 40% in vehicle-treated bleomycin mice but only 15% with AP or DQ; body weight loss averaged 3.6 g with vehicle vs about 1.6 g with AP/DQ; treadmill distance to exhaustion was >37% further with AP/DQ than vehicle.
- The paper states that histological fibrosis reductions did not reach statistical significance, despite functional benefits.
## Methods
- Human data came from LTRC control and IPF lung tissue samples, including microarray and RNA-seq datasets; the paper reports IPF n=27 and control n=10 for p16 immunohistochemistry, and transcriptome analyses stratified by FVC severity.
- The mouse study used male Ink-Attac mice given aerosolized intratracheal bleomycin (2 U/kg) or PBS, then randomized to AP20187, dasatinib plus quercetin (DQ), or vehicle at either an early prevention timepoint or a later treatment timepoint.
- Analyses included FACS of lung fibroblasts, epithelial cells, and endothelial cells, immunohistochemistry / immunofluorescence, conditioned-medium assays in IMR90 fibroblasts, traction force microscopy, RT-PCR, and statistical modeling with regression and multiple-comparison correction.
## Limitations
- The paper states that the bleomycin model spontaneously resolves, with resolution varying by factors such as genetic background and microbiome, which limits interpretation of late-stage effects.
- The authors state that they could not disentangle senescence-dependent from senescence-independent events governing fibrosis resolution.
- Lung fibrosis histology did not improve significantly after senescent-cell clearance, despite functional gains; the paper itself notes this may reflect the short time course and heterogeneity of the bleomycin model.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 8 Not checked · 94 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through secretion of the senescence-associated secretory phenotype (SASP), a broad repertoire of cytokines, chemokines, matrix remodelling proteases and growth factors, senescent cells paracrinely promote proliferation and tissue deterioration8.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
In “Senescence is a multi-step evolving process” (page unavailable), the paper says SASP-mediated paracrine signalling affects cell proliferation. In “Senescence in ageing and age-related disease” (page unavailable), it says SASP components are thought to promote proliferation of neoplastic cells and may intensify age-related tissue deterioration. The citing sentence presents those qualified effects as established and general. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by pro-ageing stressors also implicated in IPF pathogenesis, including telomere attrition, oxidative stress, DNA damage and proteome instability.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
The Abstract and 'Senescence is a multi-step evolving process' describe growth arrest, including a transition to stable cell-cycle arrest. 'Causes and effector pathways of senescence' identifies telomere erosion, DNA lesions, reactive oxygen species and proteotoxic stress as senescence-related stressors. The cited passages do not establish that senescence is evolutionarily conserved or that these stressors are implicated in IPF pathogenesis; the paper also distinguishes replicative senescence from other forms of senescence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > Senescent cell retention impairs fibrosis resolution Taken together, our in vivo results strongly support the hypothesis that elimination of senescent cells improves fibrotic pulmonary disease when treatment is initiated at the onset of pathogenesis. We next sought to test the clinically important question of whether senescent cell clearance provides comparable benefit when initiated at a timepoint when pathology has fully developed. Ink-Attac mice contained a strong senescent signature in lung fibroblasts and epithelial cells 2 weeks post-bleomycin challenge (Fig. 2), a timepoint of well-established fibrotic remodelling in the lung15. Accordingly, we administered a single dose of bleomycin or PBS through aerosolized intratracheal administration to Ink-Attac mice. Two weeks post challenge, we randomized bleomycin-exposed mice to AP, DQ or vehicle treatment groups based on change in body weight and non-invasively measured airway resistance (Penh). Mice were treated for 2 weeks and were killed 4 weeks following bleomycin or PBS exposure (Fig. 5a). Body weight monitoring revealed that, similar to our previous experiments (Fig. 4f), mice that received bleomycin lost substantial body mass, relative to mice that received PBS. Upon treatment initiation on day 14, mean body weight of mice treated with AP plateaued, while vehicle-treated, bleomycin-exposed counterparts continued to lose weight (Fig. 5a), suggestive of physical benefit afforded by senescent cell clearance, even when treatment is initiated in later-stage disease. Spontaneous resolution is an inherent limitation of the bleomycin IPF model, with the rate and variability of bleomycin-induced pathology resolution dependent on complex factors, including genetic background and the microbiome3839. Indeed, both endpoint compliance (Supplementary Fig. 6) and comparison of Penh airway resistance at endpoint (4 weeks post challenge) to measures taken at the treatment randomization timepoint (2 weeks post challenge) revealed appreciable, albeit variable, improvement in all bleomycin-exposed groups, including vehicle-treated mice, with AP-treated mice showing greatest improvement (Fig. 5b). Thus, in our hands, the 3–4-week-period following a single bleomycin exposure represents a pivotal window of natural resolution (Figs 4 and 5a,b). Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3. As we were unable to disentangle senescence-dependent and -independent events governing resolution, we queried whether p16 expression, a measure of senescent burden, was associated with indicators of disease persistence. Impaired lung function, as measured by endpoint airway resistance (Penh) (Fig. 5c) and airway compliance (Fig. 5d), correlated significantly with p16 transcript abundance. This finding is consistent with associations drawn in humans, in which increased p16 expression correlated significantly with reduced FVC, pulmonary diffusion capacity and physical function (Supplementary Fig. 1). Similarly, in bleomycin-exposed mice, expression of the inflammatory and fibrogenic SASP factors Mcp1 (Fig. 5e), Pai1 (Fig. 5f), Mmp10 (Fig. 5g) and Col1a1 (Fig. 5h) robustly correlated with p16 transcriptional activation. These results further support the notion that the presence and activities of senescent cells may dictate resolution capacity following bleomycin-induced pathology.
What the sources say
- Supportedcites [3] Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014). source
The Introduction states that aged mice have impaired fibrosis resolution associated with senescent, apoptosis-resistant myofibroblasts. The Results identify bleomycin as the lung-injury model and report accumulation of senescent myofibroblasts in aged mice with persistent fibrosis. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation.”
§ Cellular senescence mediates fibrotic pulmonary disease > Methods > Cell culture For experiments employing radiation-induced senescence, IMR90 (passages 5–7; ATCC, catalogue number CCL-186) and primary human fibroblasts (passages 3–6) were exposed to 10 Gy radiation or sham conditions using a RS2000 X-Ray Irradiator (RAD Source Technologies, Suwanee, GA). Normal bronchial epithelial cells (passages 4–7, Lot 7F3000, Lonza, Walkersville, MD) were exposed to 5 Gy or sham conditions. Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation. For SA-β-gal staining, cells were fixed for 10 min in 2% formaldehyde+0.2% glutaraldehyde in PBS at room temperature. Cells were rinsed with PBS and incubated overnight in SA-β-gal staining solution containing the following: 1 mg ml−1 X-gal, 40 mM citric acid/sodium phosphate buffer pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM sodium chloride and 2 mM magnesium chloride in water. Cells were then rinsed in PBS and stored at 4 °C until imaging. Media applied 20 days post irradiation (or sham) was collected 24 h later and was diluted with NCM to reflect equivalent source cell concentrations. ProcartaPlex immunoassays (Affymetrix eBioscience) were used for CM secretome composition assessment, according to the manufacturer's specifications. Non-irradiated IMR90 cells (passages 5–7) were treated with NCM, NCM+2 ng ml−1 TGFβ, CCM or SASP-CM and applied to downstream analyses as indicated. Primary human fibroblasts collected from human patients were authenticated through αSMA staining. For senolytic treatment, sham and irradiated primary human fibroblasts were treated with indicated concentrations of DQ or navitoclax for 3 days, starting at day 20 post irradiation or sham exposure. Cell viability after drug treatment was measured by ATPLite Kits (PerkinElmer; Waltham, MA) performed according the manufacturer's instructions. Luminescence was read using a multi-scan plate reader (Fisher). For experiments utilizing etoposide-induced senescence, IMR90 human lung fibroblasts (passage 10; ATCC) were treated for 48 h with 20 μM etoposide (Enzo Life Sciences, Farmingdale, NY). Etoposide was removed and replaced with fresh media. Six days after etoposide removal, approximately 60% of IMR90 cells were SA-β-gal positive. Cells were treated for 48 h with 20 μM D+15 μM Q or 10 μM navitoclax (or untreated control) and the percentage of SA-β-gal-positive cells was determined using a C12FDG-based senescence assay described as follows46. Briefly, etoposide-treated senescent IMR90 cells were seeded at a concentration of 5 × 103 cells per well in 96-well plates 24 h before treatment. Following addition of the drugs, the cells were incubated for 48 h under 20% O2 oxygen conditions. For fluorescence analysis of SA-β-gal activity, cells were incubated for 1 h with 100 nM Bafilomycin A1 (Calbiochem, San Diego, CA). Next, 10 μM C12FDG (Setareh Biotech, Eugene, OR) was added to the culture medium and the cells were incubated for 1.5–2 h. Ten minutes before analysis, the DNA intercalating Hoechst dye (2 μg ml−1) was added to the cells. For quantitative analysis of cell number (Hoechst staining) and number of C12FDG-positive senescent cells, a laser-based line scanning confocal imager IN Cell 6000 Analyzer was used. All samples were analysed in duplicate with three to five fields per well.
What the sources say
- Partly supportedcites [32] Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). sourceExperimental — accuracy not yet measured
In “ATTAC clears senescent adipocyte progenitor cells” (page unavailable), the paper identifies cells using p16 expression, other senescence markers, and SAβ-Gal staining. It studies naturally occurring senescent cells, however, and does not support the claim’s 21-day post-radiation condition. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, CM collected from irradiated bronchiolar epithelial cells did not activate a fibrogenic response, as measured by αSMA fibrotic activation of naive IMR90 cells (Supplementary Fig. 2), suggesting that cell-type-specific SASP composition may differentially affect pathological phenotypes within the lung.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > The secretome of senescent fibroblasts is profibrotic
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 115 claims and to verify the 5 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is in agreement with a recent report showing that the removal of senescent cells expressing high levels of p16INK4a can lead to fibrosis in mice101, whereas small-molecule senolytics appear to reduce fibrosis in several mouse tissues22,71,73,75,102.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in a mouse model of idiopathic pulmonary fibrosis (IPF), D + Q treatment improved lung compliance and reduced frailty71.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with IPF accumulate TAFs and senescence markers in lungs that increase with disease severity and activate SASP52.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of various natural flavonoids, including quercetin and fisetin, either alone or in combination with dasatinib, a pan-tyrosine kinase inhibitor, can stimulate senolysis in a variety of contexts in vitro and in vivo199,207–210.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with enhanced paracrine signaling from increased numbers of senescent neighbors and with established features of epithelial aging.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 2×
“Attenuation of age-related pathologies and extension of lifespan in chronologically aged mice has been demonstrated using the same transgenic strategy 32–34 , and improvements in lung structure and function in aged mice have recently been demonstrated using a similar suicide-gene strategy 20 .”
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 2×
“An alternative approach to transgenic senescent cell clearance is senolytics 21,22 , which may be a tractable treatment option for humans.”
Self-citationDesmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Cited by
Items 501–600 of 1,619
Insights from In Vivo Studies of Cellular Senescence
Prieto, L. I., Graves, S. I., & Baker, D. J. (2020) · Cells · doi:10.3390/cells9040954 · Cited by 41
“Natural compounds, such as quercetin and fisetin, have also been used in combination with anti-cancer drugs, particularly the pan-tyrosine kinase inhibitor dasatinib to treat naturally aged mice [20] and senescence-related diseases [66].”
BackgroundKorfei, M., MacKenzie, B., & Meiners, S. (2020) · European Respiratory Review · doi:10.1183/16000617.0126-2020 · Cited by 45
Pathophysiological Roles of Stress-Activated Protein Kinases in Pulmonary Fibrosis
Kasuya, Y., Kim, J., Hatano, M., Tatsumi, K., & Matsuda, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116041 · Cited by 42
Cellular senescence promotes cancer metastasis by enhancing soluble E-cadherin production
Kawaguchi, K., Komoda, K., Mikawa, R., Asai, A., & Sugimoto, M. (2021) · iScience · doi:10.1016/j.isci.2021.103022 · Cited by 43
Venkatesh, G., Suganesh, R., Jayaprakash, J., Srinivasan, M., & Prabu, K. M. (2021) · Chemical Physics Letters · doi:10.1016/j.cplett.2021.139237 · Cited by 41
Converging Paths of Pulmonary Arterial Hypertension and Cellular Senescence
van der Feen, D. E., Berger, R. M. F., & Bartelds, B. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0329tr · Cited by 40
White, T. L., Deshpande, N., Kumar, V., Gauthier, A. G., & Jurkunas, U. V. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.445 · Cited by 43
Self-citationLorenzo, E. C., Torrance, B. L., Keilich, S. R., Al‐Naggar, I. M., Harrison, A. G., Xu, M., Bartley, J. M., & Haynes, L. (2021) · Aging Cell · doi:10.1111/acel.13525 · Cited by 50
LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis
Shi, X., Chen, Y., Liu, Q., Mei, X., Liu, J., Tang, Y., Luo, R., Sun, D., Ma, Y., Wu, W., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.711 · Cited by 44
Fulminant lung fibrosis in non-resolvable COVID-19 requiring transplantation
Jyothula, S., Peters, A. M., Liang, Y., Bi, W., Shivshankar, P., Yau, S., Garcha, P., Yuan, X., Akkanti, B. H., Collum, S. D., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104351 · Cited by 42
“52 Thus, taken together our results demonstrate a unique hyper-fi brotic phenotype in NR-COVID-19 that appears on average 120 days after testing positive for SARS-CoV-2 and is dominated by increased pro-fi brotic mediators and hyperexpression of CTHRC1, KRT5, and KRT8.”
Nath, K. A., O’Brien, D. R., Croatt, A. J., Grande, J. P., Ackerman, A. W., Nath, M. C., Yamada, S., Terzic, A., Tchkonia, T., Kirkland, J. L., et al. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00308.2018 · Cited by 40
Self-citationBiomarkers of cellular senescence in idiopathic pulmonary fibrosis
Aversa, Z., Atkinson, E. J., Carmona, E. M., White, T. A., Heeren, A. A., Jachim, S. K., Zhang, X., Cummings, S. R., Chiarella, S. E., Limper, A. H., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02403-8 · Cited by 39
Self-citationMiragem, A. A., & de Bittencourt, P. I. H. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx020 · Cited by 41
FOXL1 Regulates Lung Fibroblast Function Via Multiple Mechanisms
Miyashita, N., Horie, M., Suzuki, H. I., Saito, M., Mikami, Y., Okuda, K., Boucher, R. C., Suzukawa, M., Hebisawa, A., Saito, A., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0396oc · Cited by 40
“To explore the clinical significance of FOXL1 expression in the lungs, we compared the transcript levels of FOXL1 between normal and IPF lung tissues using the GSE92592 dataset (42) and found higher FOXL1 expression levels in IPF lung tissue (Figure 7A).”
MethodA guide to senolytic intervention in neurodegenerative disease
Lee, S., Wang, E. Y., Steinberg, A. B., Walton, C. C., Chinta, S. J., & Andersen, J. K. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111585 · Cited by 39
Role of senescence in the chronic health consequences of COVID-19
Wissler Gerdes, E. O., Vanichkachorn, G., Verdoorn, B. P., Hanson, G. J., Joshi, A. Y., Murad, M. H., Rizza, S. A., Hurt, R. T., Tchkonia, T., & Kirkland, J. L. (2022) · Translational Research · doi:10.1016/j.trsl.2021.10.003 · Cited by 38
Self-citationSenescent cells at the crossroads of aging, disease, and tissue homeostasis
Kuehnemann, C., & Wiley, C. D. (2023) · Aging Cell · doi:10.1111/acel.13988 · Cited by 50
“…and diabetes (Aguayo-Mazzucato et al., 2019; Amor et al., 2020; Baar et al., 2017; Baker et al., 2016; Chang et al., 2016; Childs et al., 2016; Farr et al., 2017; Jeon et al., 2017; Ogrodnik et al., 2017; Palmer et al., 2019; Schafer et al., 2017; Thompson et al., 2019; Wiley, Liu, et al., 2019).”
BackgroundAging and atrial fibrillation: A vicious circle
Gao, P., Gao, X., Xie, B., Tse, G., & Liu, T. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131445 · Cited by 44
Takaya, K., & Kishi, K. (2024) · Biogerontology · doi:10.1007/s10522-024-10103-z · Cited by 50
“This drug combination facilitates senescent cell elimination to exert beneficial effects in idiopathic pulmonary fibrosis (Schafer et al. 2017), limit bone loss (Farr et al. 2017), cardiovascular-related diseases (Nieto et al. 2024), knee osteoarthritis (Guo et al. 2022), and ameliorate radial skin…”
Zhang, Y., Liu, J., Zheng, R., Hou, K., Zhang, Y., Jia, T., Lu, X., Samarawickrama, P. N., Jia, S., He, Y., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155882 · Cited by 44
Bhardwaj, S., Gautam, R. K., & Kushwaha, S. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.08.003 · Cited by 55
Anti‐inflammaging effects of human alpha‐1 antitrypsin
Yuan, Y., DiCiaccio, B., Li, Y., Elshikha, A. S., Titov, D., Brenner, B. R., Seifer, L., Pan, H., Karic, N., Akbar, M. A., et al. (2017) · Aging Cell · doi:10.1111/acel.12694 · Cited by 38
“The chronic inflammation induced by SASP is associated with aging-related degenerative diseases, fibrotic pulmonary disease, and cancer (Coppe et al., 2008; Franceschi & Campisi, 2014; Schafer et al., 2017).”
BackgroundSundar, I. K., Rashid, K., Gerloff, J., Rangel‐Moreno, J., Li, D., & Rahman, I. (2018) · The FASEB Journal · doi:10.1096/fj.201701518r · Cited by 38
“Recently, the use of the INK-ATTAC transgenic mice for removal of senescent cells improved lung functionandSASP in the mouse model of bleomycin-induced pulmonary fibrosis (49).”
BackgroundMethodDecoding fibrosis: Mechanisms and translational aspects
Schaefer, L. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.04.009 · Cited by 40
Role of Senescent Renal Cells in Pathophysiology of Diabetic Kidney Disease
Wiley, C. D. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01314-y · Cited by 39
Han, X., Yuan, T., Zhang, J., Shi, Y., Li, D., Dong, Y., & Fan, S. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17333 · Cited by 38
Alzahrani, K. A., & Ismail, A. A. (2022) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2022.114298 · Cited by 38
Cellular senescence as a therapeutic target to improve renal transplantation outcome
van Willigenburg, H., de Keizer, P. L. J., & de Bruin, R. W. F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.015 · Cited by 38
Maturu, P., Liang, Y. W., Androutsopoulos, V. P., Jiang, W., Wang, L., Tsatsakis, A. M., & Couroucli, X. I. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.02.026 · Cited by 43
“T protective effect of QU in heart and lung injury has also been reported (Griffiths et al., 2016; Hertog et al., 1993; Schafer et al., 2017; Takashima et al., 2014).”
BackgroundDynamic regulation of myofibroblast phenotype in cellular senescence
López‐Antona, I., Contreras‐Jurado, C., Luque‐Martín, L., Carpintero‐Leyva, A., González‐Méndez, P., & Palmero, I. (2022) · Aging Cell · doi:10.1111/acel.13580 · Cited by 40
Hou, J., Huang, Y. L., Fu, L., Sun, M., Wang, L., Guo, R., Chen, L., & Lv, C. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c03640 · Cited by 38
Human senescent fibroblasts trigger progressive lung fibrosis in mice
Hernández‐González, F., Prats, N., Ramponi, V., Lopez-Dominguez, J. A., Meyer, K. R., Aguilera, M., Martín, M. I. M., Martínez, D., Agustí, A. G. N., Faner, R., et al. (2023) · Aging · doi:10.18632/aging.204825 · Cited by 45
Mitochondrial quality control in lung diseases: current research and future directions
Liu, J., Wang, J., Xiong, A., Zhang, L., Zhang, Y., Liu, Y., Xiong, Y., Li, G., & He, X. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1236651 · Cited by 42
Loss of ANT1 Increases Fibrosis and Epithelial Cell Senescence in Idiopathic Pulmonary Fibrosis
Sui, J., Boatz, J. C., Shi, J., Hu, Q., Li, X., Zhang, Y., Königshoff, M., & Kliment, C. R. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0315oc · Cited by 45
Cheng, X., Jiang, S., Pan, B., Xie, W., & Meng, J. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01964-3 · Cited by 40
“The median survival of newly diagnosed adult IPF patients (typically over 60 years old) is less than 5 years [2].”
BackgroundLi, X., Liu, Y., Tang, Y., & Xia, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1474688 · Cited by 65
Lei, Y., Zhong, C., Zhang, J., Zheng, Q., Xu, Y., Li, Z., Huang, C. K., & Ren, T. (2024) · Oncogene · doi:10.1038/s41388-024-03236-5 · Cited by 53
“Senescence is considered a pivotal pathogenic mechanism in IPF development [23]; although the precise mechanisms of cellular senescence in IPF have not been fully elucidated, they are believed to involve various intrinsic (genetic abnormalities) and extrinsic (oncogene activation and oxidative…”
Signal Transduction, Ageing and Disease
Zhang, L. J., Yousefzadeh, M. J., Suh, Y., Niedernhofer, L. J., & Robbins, P. D. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_9 · Cited by 42
Self-citationMetabolic reprogramming: A driver of cigarette smoke-induced inflammatory lung diseases
Li, L., Yang, D. C. H., & Chen, C. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.438 · Cited by 43
Chronic lung diseases: prospects for regeneration and repair
Barnes, P. J., Anderson, G. P., Fagerås, M., & Belvisi, M. G. (2021) · European Respiratory Review · doi:10.1183/16000617.0213-2020 · Cited by 39
Alsuraih, M., O’Hara, S. P., Woodrum, J. E., Pirius, N. E., & LaRusso, N. F. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100250 · Cited by 37
Siekacz, K., Piotrowski, W. J., Iwański, M. A., Górski, P., & Białas, A. J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9932442 · Cited by 44
“Indeed, senescence contributes to age-related respiratory diseases including IPF [90].”
BackgroundBarnes, P. J. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_3 · Cited by 40
Senopathies-Diseases Associated with Cellular Senescence
Lushchak, O., Schosserer, M., & Grillari, J. (2023) · Biomolecules · doi:10.3390/biom13060966 · Cited by 35
“An accumulation of senescent cells induces fibrotic pulmonary disease, especially in idiopathic pulmonary fibrosis [81].”
BackgroundInfluentialHong, X., Wang, L., Zhang, K., Liu, J., & Liu, J. (2022) · Cells · doi:10.3390/cells11050877 · Cited by 38
Death-seq identifies regulators of cell death and senolytic therapies
Colville, A., Liu, J., Rodríguez-Mateo, C., Thomas, S. M., Ishak, H. D., Zhou, R., Klein, J. D. D., Morgens, D. W., Goshayeshi, A., Salvi, J. S., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.08.008 · Cited by 41
Chu, L., Zhuo, J., Huang, H., Chen, W., Zhong, W., Zhang, J., Meng, X., Zou, F., Cai, S., Zou, M., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176459 · Cited by 44
Selman, M., Martinez, F. J., & Pardo, A. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1166pp · Cited by 35
Türkkan, G., Willems, Y. C. P., Hendriks, L. E. L., Mostard, R. L. M., Conemans, L. H., Gietema, H. A., Mitea, C., Peeters, S., & Ruysscher, D. D. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.11.020 · Cited by 38
Hurvitz, N., Elkhateeb, N., Sigawi, T., Rinsky‐Halivni, L., & Ilan, Y. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.1044038 · Cited by 38
“Variability in cellular senescence: Senescence occurs in response to danger signals, activated oncogenes, and metabolic abnormalities (Schafer et al., 2017).”
BackgroundWu, F., Zhang, Z., Wang, M., Ma, Y., Verma, V., Xiao, C., Zhong, T., Chen, X., Wu, M., Yu, J., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.02.005 · Cited by 40
A BDNF-TrkB autocrine loop enhances senescent cell viability
Anerillas, C., Herman, A. B., Munk, R., Garrido, A., Lam, K.-W. G., Payea, M. J., Rossi, M., Tsitsipatis, D., Martindale, J. L., Piao, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33709-8 · Cited by 35
Mesenchymal cells in the Lung: Evolving concepts and their role in fibrosis
Ligresti, G., Raslan, A., Hong, J., Caporarello, N., Confalonieri, M., & Huang, S. K. (2023) · Gene · doi:10.1016/j.gene.2022.147142 · Cited by 43
Self-citationProgressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium
Bridges, J. P., Vladar, E. K., Kurche, J. S., Krivoi, A., Stancil, I. T., Dobrinskikh, E., Hu, Y., Sasse, S. K., Lee, J. S., Blumhagen, R. Z., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci183836 · Cited by 46
“…its biosynthesis and secretion. mechanisms involving particle deposition (20, 25, 26), mucociliary dysfunction, epithelial injury with attendant persistent inflammation (27–29), stem cell exhaustion (30–32), and cell senescence (32–35) represent key drivers of the persistent fibrotic process.”
Age-Related Changes in Immunological and Physiological Responses Following Pulmonary Challenge
Miller, E. J., & Linge, H. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061294 · Cited by 36
“Elegant work on idiopathic pulmonary fibrosis has recently shown that senescence markers are present within the lungs of this patient group and, interestingly depleting the senescent cells restored pulmonary health in an animal model [60].”
BackgroundStereotactic Lung Irradiation in Mice Promotes Long-Term Senescence and Lung Injury
Soysouvanh, F., Benadjaoud, M. A., Santos, M. D., Mondini, M., Lavigne, J., Bertho, A., Buard, V., Tarlet, G., Adnot, S., Deutsch, É., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.12.039 · Cited by 42
Mitochondria, Aging, and Cellular Senescence: Implications for Scleroderma
Bueno, M., Papazoglou, A., Valenzi, E., Rojas, M. M., Lafyatis, R., & Mora, A. L. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00920-9 · Cited by 40
CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis
Birnhuber, A., Egemnazarov, B., Biasin, V., Rad, E. B., Wygrecka, M., Olschewski, H., Kwapiszewska, G., & Marsh, L. M. (2020) · Respiratory Research · doi:10.1186/s12931-020-01433-w · Cited by 33
Cruz, T., Jia, M., Sembrat, J., Tabib, T., Agostino, N. R., Bruno, T. C., Vignali, D. A. A., Sánchez, P. G., Lafyatis, R., Mora, A. L., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202012-4418le · Cited by 39
Role of autophagy in lung diseases and ageing
Zhang, Y., Zhang, J., & Fu, Z. (2022) · European Respiratory Review · doi:10.1183/16000617.0134-2022 · Cited by 41
Cellular senescence and neurodegeneration
Holloway, K., Neherin, K., Dam, K. U., & Zhang, H. (2023) · Human Genetics · doi:10.1007/s00439-023-02565-x · Cited by 43
“Senolytic treatment reduces senescent cell burden in animal models and improves aging-associated dysfunction in various organs and tissues including adipose tissue, blood, bone, brain, heart, kidney, liver, and lung (Zhu et al. 2015, 2016; Xu et al. 2015, 2018; Chang et al. 2016; Roos et al. 2016; Childs et al. 2016;…”
BackgroundWang, P., Yan, Z., Zhou, P., & Gu, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315014 · Cited by 37
Role of cellular senescence in inflammatory lung diseases
Xie, C. H., Yalikun, M., Luo, Q., & Dong, J. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.02.001 · Cited by 33
Cheng, P., Yu, F., Chen, S.-J., Feng, X. M., Jia, Z.-H., Hu, S., Cui, X.-L., Zhou, Y., Niu, Q., Liang, L., et al. (2024) · Environmental Pollution · doi:10.1016/j.envpol.2024.123674 · Cited by 38
IL-23R is a senescence-linked circulating and tissue biomarker of aging
Carver, C. M., Rodriguez, S. L., Atkinson, E. J., Dosch, A. J., Asmussen, N. C., Gomez, P. T., Leitschuh, E. A., Espíndola‐Netto, J. M., Jeganathan, K. B., Whaley, M. G., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00752-7 · Cited by 43
“Sample sizes were determined according to current standards used for mice in experimental biology, based on the minimal number of mice required to detect significance with an alpha set at 0.05 in two-tailed test in a standard powered experiment 6 .”
InfluentialSelf-citationEnhancing immunity during ageing by targeting interactions within the tissue environment
Bracken, O. V., Maeyer, R. P. H. D., & Akbar, A. N. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01126-9 · Cited by 45
New therapeutics based on emerging concepts in pulmonary fibrosis
Sontake, V., Gajjala, P. R., Kasam, R. K., & Madala, S. K. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1552262 · Cited by 34
“However, visible fibrosis was not altered as evidenced by histopathological score [104].”
BackgroundMercader, J., Truyols-Vives, J., Río, C., López-Safont, N., Sala, E., & Chaplin, A. M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176051 · Cited by 36
“Importantly, the removal of senescent cells with dasatinib and quercetin ameliorated pulmonary function in experimental animals [6].”
BackgroundRecent developments in the pathobiology of lung myofibroblasts
Jiang, D., Dey, T., & Liu, G. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2021.1829972 · Cited by 36
Hermansky-Pudlak Syndrome and Lung Disease: Pathogenesis and Therapeutics
Velázquez-Díaz, P., Nakajima, E., Sorkhdini, P., Hernandez-Gutierrez, A., Eberle, A. T., Yang, D., & Zhou, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.644671 · Cited by 40
Biological Aspects of Inflamm-Aging in Childhood Cancer Survivors
Rossi, F., Paola, A. D., Pota, E., Argenziano, M., Pinto, D., Marrapodi, M. M., Leva, C. D., Martino, M. D., & Tortora, C. (2021) · Cancers · doi:10.3390/cancers13194933 · Cited by 39
IRE1α drives lung epithelial progenitor dysfunction to establish a niche for pulmonary fibrosis
Auyeung, V. C., Downey, M. S., Kathiriya, J. J., Thamsen, M., Wenger, T. A., Backes, B. J., Brumwell, A. N., Chapman, H. A., Sheppard, D., & Papa, F. R. (2022) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00408.2021 · Cited by 37
Senescent Cells Accumulate in Systemic Sclerosis Skin
Shi, B., Tsou, P., Ma, F., Mariani, M., Mattichak, M. N., LeBrasseur, N. K., Chini, E. N., Lafyatis, R., Khanna, D., Whitfield, M. L., et al. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2022.09.652 · Cited by 35
“Fibroblasts isolated from idiopathic pulmonary fibrosis lungs (Schafer et al., 2017) and from SSc skin (Dumit et al.”
BackgroundSelf-citationSamakkarnthai, P., Saul, D., Zhang, L., Aversa, Z., Doolittle, M. L., Sfeir, J. G., Kaur, J., Atkinson, E. J., Edwards, J. R., Russell, G. G., et al. (2023) · Aging · doi:10.18632/aging.204701 · Cited by 34
“Further, senescent cell clearance in mice also alleviates the progression of systemic diseases, including cardiovascular disease [15, 16], physical frailty [13], pulmonary fibrotic disease [17], cancer [18], and bone loss related to aging [19] or cancer treatments [20, 21].”
Self-citationContext‐dependent roles of cellular senescence in normal, aged, and disease states
Moiseeva, V., Cisneros, A., Cobos, A. C., Tarrega, A. B., Oñate, C. S., Perdiguero, E., Serrano, A. L., & Muñoz‐Cánoves, P. (2023) · The FEBS Journal · doi:10.1111/febs.16573 · Cited by 34
Cellular Senescence Triggers Altered Circadian Clocks With a Prolonged Period and Delayed Phases
Ahmed, R., Nakahata, Y., Shinohara, K., & Bessho, Y. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.638122 · Cited by 34
Choi, S. M., Mo, Y., Bang, J., Ko, Y. G., Ahn, Y. H., Kim, H. Y., Koh, J., Yim, J., & Kang, H. (2023) · Respiratory Research · doi:10.1186/s12931-023-02357-x · Cited by 36
Homeostatic chemokines as putative therapeutic targets in idiopathic pulmonary fibrosis
Russo, R. C., Quesniaux, V. F. J., & Ryffel, B. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.10.003 · Cited by 33
Aging, senescence, and cutaneous wound healing—a complex relationship
O’Reilly, S., Markiewicz, E., & Idowu, O. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1429716 · Cited by 48
“Indeed the selective elimination of senescent cells via the senolytic cocktail dasatanib and quercetin in mouse models of lung fi brosis led to signi fi cantly reduced senescent cells and fi brosis, underpinning the importance of senescence (59).”
BackgroundModeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice
Habiel, D. M., Espíndola, M. S., Coelho, A. L., & Hogaboam, C. M. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.12.020 · Cited by 35
Modeling Progressive Fibrosis with Pluripotent Stem Cells Identifies an Anti-fibrotic Small Molecule
Vijayaraj, P., Minasyan, A., Durra, A., Karumbayaram, S., Mehrabi, M., Aros, C. J., Ahadome, S. D., Shia, D. W., Chung, K., Sandlin, J. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.019 · Cited by 35
“Senescent cells (20%–30%) were observed with p16INK4A staining in the iFA model during progression of the fibrotic phenotype, consistent with what has been described in fibrotic lung (Schafer et al., 2017), liver (Lasry and Ben-Neriah, 2015), and kidney tissue (Sturmlechner et al.”
Resultvan Batenburg, A. A., Kazemier, K. M., van Oosterhout, M. F. M., van der Vis, J. J., van Es, H. W., Grutters, J. C., Goldschmeding, R., & van Moorsel, C. H. M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226785 · Cited by 34
NADPH Oxidase Inhibition in Fibrotic Pathologies
Bernard, K. F., & Thannickal, V. J. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8032 · Cited by 34
“In addition to the pathogenic mechanisms described above, cellular senescence has been the focus of numerous studies following the observation that senescent cells accumulate in the fibrotic lung (98, 215).”
BackgroundInfluentialRiou, M., Alfatni, A., Charles, A., Andrès, E., Pistea, C., Charloux, A., & Gény, B. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051253 · Cited by 37
van Batenburg, A. A., Kazemier, K. M., van Oosterhout, M. F. M., van der Vis, J. J., Grutters, J. C., Goldschmeding, R., & van Moorsel, C. H. M. (2021) · ERJ Open Research · doi:10.1183/23120541.00691-2020 · Cited by 40
The plasticity of fibroblasts: A forgotten player in the aging process
Salminen, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101995 · Cited by 38
Aryl hydrocarbon receptor: From pathogenesis to therapeutic targets in aging-related tissue fibrosis
Yang, C.-E., Wang, Y., Hua, M.-R., Miao, H., Zhao, Y., & Cao, G. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101662 · Cited by 36
Senescent cells, senolytics and tissue repair: the devil may be in the dosing
Khosla, S. (2023) · Nature Aging · doi:10.1038/s43587-023-00365-6 · Cited by 32
Development of lung tissue models and their applications
Petpiroon, N., Netkueakul, W., Sukrak, K., Wang, C., Liang, Y. T., Wang, M., Liu, Y., Li, Q., Kamran, R., Naruse, K., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122208 · Cited by 43
Lactate accumulation induced by Akt2‐PDK1 signaling promotes pulmonary fibrosis
Sun, Z., Ji, Z., He, W., Duan, R., Qu, J., & Yu, G. (2024) · The FASEB Journal · doi:10.1096/fj.202302063rr · Cited by 37
Nanocarriers for natural polyphenol senotherapeutics
Joma, N., Bielawski, P., Saini, A., Kakkar, A. K., & Maysinger, D. (2024) · Aging Cell · doi:10.1111/acel.14178 · Cited by 36
Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐Senolytics
Zhang, H., Xu, X., Shou, X., Liao, W., Jin, C., Chen, C., Zhang, C. Y., Gao, W., Zhang, J., Ge, W., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401085 · Cited by 39
Shen, M., Fu, J., Zhang, Y., Chang, Y., Li, X., Cheng, H., Qiu, Y., Shao, M., Han, Y., Zhou, Y., et al. (2024) · Aging Cell · doi:10.1111/acel.14229 · Cited by 37
“These data suggest that pulmonary fibrosis is an age-related disease, consistent with the results of previous studies (Guan et al., 2022; Schafer et al., 2017).”
BackgroundResultSenolytic treatment for low back pain
Mannarino, M., Cherif, H., Darband, S. G., Martinez, O. W., Sheng, K., Cousineau, E., Lee, S., Millecamps, M., Gao, C., Gilbert, A., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr1719 · Cited by 37
“Similarly to our results, senolytic combination treatment of D + Q is more efficient in the treatment of idiopathic fibrosis, diabetic kidney disease, and age-related diseases such as bone loss, physical dysfunction, and shortening health span and life span ( 27 , 116 – 118 ).”
Subedi, S., Guntipally, M., Suwal, N., Thapa, R., Bashyal, S., Panth, N., Gupta, G., MacLoughlin, R. J., Oliver, B. G. G., Dua, K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102813 · Cited by 40
Therapeutic targeting of 15-PGDH in murine pulmonary fibrosis
Smith, J. N. P., Witkin, M. D., Jogasuria, A. P., Christo, K. F., Raffay, T. M., Markowitz, S. D., & Desai, A. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-68336-0 · Cited by 33
Faniyi, A. A., Hughes, M., Scott, A., Belchamber, K. B. R., & Sapey, E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15759 · Cited by 35
“improved pulmonary function and physical health, although lung fibrosis was visibly unaltered (Schafer et al., 2017).”
BackgroundGuaraldi, G., Milić, J., Cesari, M., Leibovici, L., Mandreoli, F., Missier, P., Rozzini, R., Cattelan, A. M., Motta, F., Mussini, C., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101686 · Cited by 34
Potential Clinical Implications of Senotherapies for Cardiovascular Disease
Suda, M., Katsuumi, G., Tchkonia, T., Kirkland, J. L., & Minamino, T. (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0657 · Cited by 39
Self-citationCellular Senescence: A Troy Horse in Pulmonary Fibrosis
Wan, R., Wang, L., Zhu, M., Li, W., Duan, Y., & Yu, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216410 · Cited by 36
“Importantly, the selective removal of senescent cells rejuvenates pulmonary health and alleviates PF in aged mice [29].”
BackgroundInfluential
Metadata
- Authors
- Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D. L., Brooks, R. W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y. S., Tchkonia, T., Robbins, P. D., Aubry, M. C., Passos, J. F., Kirkland, J. L., Tschumperlin, D. J., Kita, H., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Newcastle University (GB)
- Scripps Research Institute (US)
- Corresponding author
- LeBrasseur, Nathan K.
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-23
- Volume
- 8
- Issue
- 1
- Pages
- 14532-14532
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5331226
- OpenAlex
- W2591114726
- Cited by
- 1,613
- References
- 52
- Citations by year
- 2026: 195 · 2025: 205 · 2024: 193 · 2023: 193 · 2022: 192 · 2021: 181 · 2020: 176 · 2019: 128 · 2018: 107 · 2017: 42
- FWCI
- 91.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Mayo Clinic (UL1-TR000135)
- Glenn Foundation for Medical Research
- Louisiana Transportation Research Center
- Georgia Clinical and Translational Science Alliance (UL1 TR000135)
- Noaber Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health (UL1TR000135, 2r01hl092961-13)
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/K017314/1, BB/H022384/1)
- National Institute on Aging (R01AG053832, R01AG013925, R37AG013925)
- National Heart, Lung, and Blood Institute (R01-HL-092961)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- cellular senescence, idiopathic pulmonary fibrosis, senolytics, senescence-associated secretory phenotype, senescent fibroblasts, p16, bleomycin-induced lung injury, interstitial pulmonary fibrosis, suicide gene therapy, lung function
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Male, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Proteome, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.